Curis Inc. (CRIS, Financial) experienced a notable stock movement, with a rapid increase of 6.53% in its share price. The stock is currently priced at $5.38 per share, with a trading volume of 18,255 shares and a turnover rate of 0.31%. The stock's volatility stands at 7.62%.
Recent financial reports indicate that Curis reported revenue of $2.55 million and a net loss of $11.80 million, resulting in an earnings per share (EPS) of -$2.03. The company also achieved a gross profit of $2.47 million, with a price-to-earnings (P/E) ratio of -0.66. At present, there are no institutional ratings available for Curis, which cover buy, hold, or sell recommendations.
Within the biotechnology sector, which saw an overall gain of 0.32%, Curis is part of a group of stocks displaying significant activity. Companies like NLS Pharmaceutics, Seastar Medical Holding, and Pasithea Therapeutics have shown substantial increases, while Aditxt, Tempest Therapeutics, and Clearmind Medicine have been notably active with high turnover rates.
Curis Inc. specializes in developing and commercializing innovative drugs and therapies in the fields of immuno-oncology and precision oncology. The company's pipeline targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphoma, and hematologic cancers, with products such as CUDC-907, CA-170, CA-4948, CA-327, and Erivedge.
